Roche acquired a portfolio of experimental cystic fibrosis therapies, including a candidate that has the potential to treat all patients with the disease.
Spero Therapeutics and the Bill & Melinda Gates Foundation teamed up to take on the challenge of a lung infection designated as a critical concern by the World Health Organization.
A bacteriophage is a virus that infects bacteria. They are not typically used to treat bacterial infections, but in desperate cases, they have been used to treat particularly antibiotic-resistant infections.
AstraZeneca took another step to refocus on priority drugs by selling U.S. rights to Synagis for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.
The Food and Drug Administration approved Insmed Inc.’s lead drug Arikayce to treat a rare chronic lung disease.
Insmed Inc. said its drug for the treatment of a rare lung disorder met the main goal in a key study, sending its shares soaring in premarket trading.
Aradigm Corp.’s inhaled antibiotic for a rare, incurable disorder affecting the lungs failed a late-stage study, sending the company’s shares down in premarket trading.